Cytek Biosciences, Inc. (CTKB)
NMS – Real Time Price. Currency in USD
4.72
-0.03 (-0.53%)
Market open: Aug 12, 2026, 10:59 AM EDT
4.82
+0.08 (1.69%)
Previous after-hours: Aug 11, 2026, 7:55 PM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
4.72
-0.03 (-0.53%)
Market open: Aug 12, 2026, 10:59 AM EDT
4.82
+0.08 (1.69%)
Previous after-hours: Aug 11, 2026, 7:55 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $73.8M significantly exceed its total debt $35.2M, ensuring strong financial flexibility
Total current assets $377.9M exceed Total current liabilities $84.3M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (1.1), showcasing prudent financial management
Interest coverage ratio (-40.6x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$849.0K limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 4.48 | 3.40 | 10 | |
| Quick ratio | 3.86 | 2.52 | 10 | |
| Debt to Equity | 0.11 | 1.11 | 9.0 | |
| Debt to Assets | 0.08 | 1.58 | 9.0 | |
| Interest coverage | -40.57 | 4.33 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 164M | 193M | 200M | 201M | 207M |
| Gross Profit | 102M | 109M | 111M | 104M | 110M |
| Operating Income | -1M | -26M | -23M | -40M | -45M |
| Net Income | 3M | -12M | -6M | -67M | -81M |
| EBITDA | 4M | -17M | -13M | -28M | -33M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 1.25 | -1210.33 | 2.0 |
| Next quarter | 2.43 | 99.02 | 6.5 |
| Current year | 3.94 | 44.71 | 7.0 |
| Next year | 6.59 | 40 | 7.5 |
| Weighted average score | 5.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 9.07 | 35.56 | 40 | 82.69 | 9.0 |
| Y/Y | 5.57 | -117.76 | -124.99 | 42.21 | 4.3 |
| 3y average | 7.35 | -508.8 | 28.54 | 1105.07 | 6.5 |
| 5y average | 17.61 | -125.47 | 1.96 | -1029.11 | 3.5 |
| Weighted average score | 5.8 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |